Welcome Dallas Tester, our new VP, Engineering! At Foresight, Dallas will oversee the development of software and bioinformatics pipelines that produce test results and ensure Foresight’s software and devices are compliant and meet regulatory requirements. #NewEmployee

At the Advancing Precision Medicine conference, Dr. Mark Roschewski of the Lymphoid Malignancies Branch at the NCI's Center for Cancer Research, demonstrated how ctDNA testing provides more accurate end-of-therapy assessment than PET scans. Check it out:

. @PitchBook analysts share their #JPM2025 takeaways, including the progression of disease diagnostics such as #MRD, noting Foresight Diagnostics as leading the way. Catch that around minute 26: #JPM25 #HealthcareInvestment #Diagnostics #Cancer

This morning, our CEO @JakeChabon presented at #JPM2025. It was great to connect with industry leaders and share our groundbreaking work on ultra-sensitive minimal residual disease (MRD) detection. Learn more about Foresight:

Attending #JPM2025? Our CEO Jake Chabon is presenting on Wed., Jan. 15, 2025, at 7:30 a.m. PT. We look forward to engaging with industry leaders, investors, and partners. To schedule a meeting, please contact InvestorRelations@foresight-dx.com. #MRD #LiquidBiopsy

Foresight is thrilled to share that #ctDNA #MRD testing is now included in @NCCN Guidelines for #DLBCL – a first for this indication. The guidelines now recommend ctDNA-MRD testing to evaluate PET-positive results at end of first-line DLBCL therapy.

2024 was an exceptional year for Foresight Diagnostics. We're proud of what we accomplished, and we're ready for continued momentum in 2025 as we work to deliver innovative cancer diagnostics to patients. Check out our 2024 milestones and 2025 goals here:

The Foresight Diagnostics team is pleased to welcome Lena Caron, our new Associate Lab Director! At Foresight, Lena will oversee laboratory operations and ensure a safe, efficient and compliant environment for our patient testing.

Foresight Diagnostics team members came to Boulder this month for our all-hands meeting and holiday party, with highlights including a founder fireside chat, company trivia, a recap of 2024 accomplishments, and an ugly sweater contest. Happy holidays from the Foresight team!

Last week, our cofounder @JakeChabon joined his diagnostic industry peers for a panel discussion on #MRD and the importance of ultra-sensitive approaches at the @TDBank_US Diagnosing Tomorrow: Tools & Technologies for the Next Decade event in New York.

We are excited to share that our CEO Jake Chabon will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 at 7:30 a.m. PT about minimal residual disease (MRD) detection. Read our press release: #MRD #ctDNA

Thanks to everyone who stopped by our #SABCS24 poster last week, and thanks again to our research partners at @MSKCancerCenter. Did you miss our poster? Check it out

🎉 Congrats to our cofounder & Scientific Advisory Board member, @AshAlizadeh, for being honored by @LLSusa for his transformative work in blood cancer research! 🧬 His commitment inspires our work to help change current treatment paradigms:

What an amazing #ASH24! 🙌The crowd was packed for our Clinical Trial Showcase with @AllogeneTx with an overview of the ALPHA3 trial, along with a great panel reception discussing #MRD endpoints. Posters and slides coming soon or email BD@foresight-dx.com

It’s almost time for @SABCSSanAntonio, where we’ll be sharing new #breastcancer data with our collaborators @MSKCancerCenter. Look for our poster analysis showing that ctDNA clearance following perioperative treatments is strongly associated with favorable survival outcomes

Tomorrow is the day! 🎉 Will you be at #ASH24? Stop by our Clinical Trial Showcase as well as three opportunities for an #Oncology Expert Q&A, once each day. Learn about #MRD tech redefining #lymphoma care and #DrugDevelopment:

We are pleased to share that our Foresight CLARITY #MRD test will be used in @ColumbiaMed's SHORTEN-ctDNA trial, which aims to evaluate the ability to utilize MRD detection to enable real-time treatment optimization for patients with #DLBCL.

Next week we will share new data on Foresight CLARITY ultra-sensitive MRD detection in early-stage #breastcancer at the 2024 @SABCSSanAntonio, in collaboration with @MSKCancerCenter. Hope to see you there.

Later this week! 🚨 Foresight Diagnostics is presenting on ultra-sensitive #MRD testing with Foresight CLARITY. Visit booth 3423 or email BD@foresight-dx.com. See our #ASH24 presentations.

As #LCAM2024 closes, we honor the resilience of those affected by lung cancer and affirm our commitment to advancing solutions. #1in16 people will receive a diagnosis in their lifetime per @lcrf_org. Read our study on #MRD and #LungCancer: